Accès gratuit
| Numéro |
Biologie Aujourd'hui
Volume 204, Numéro 1, 2010
|
|
|---|---|---|
| Page(s) | 81 - 86 | |
| Section | L'immunothérapie passive aujourd'hui | |
| DOI | https://doi.org/10.1051/jbio/2009048 | |
| Publié en ligne | 8 avril 2010 | |
- Albrecht M.T., Li H., Williamson E.D., LeButt C.S., Flick-Smith H.C., Quinn C.P., Westra H., Galloway D., Mateczun A., Goldman S., Groen H. Baillie L.W., Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun, 2007, 75, 5425-5433. [CrossRef] [PubMed] [Google Scholar]
- Flick-Smith H.C., Waters E.L., Walker N.J., Miller J., Stagg A.J., Green M., Williamson E.D., Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathog, 2005, 38, 33-40. [CrossRef] [PubMed] [Google Scholar]
- Hill J., Eyles J.E., Elvin S.J., Healey G.D., Lukaszewski R.A., Titball R.W., Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun, 2006, 74, 3068-3070. [CrossRef] [PubMed] [Google Scholar]
- Holty J.E., Bravata D.M., Liu H., Olshen R.A., McDonald K.M., Owens D.K., Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med, 2006, 144, 270-280. [PubMed] [Google Scholar]
- Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., Gerbeding J., Hauer J., Hughes J., McDade J., Osterholm M.T., Parker G., Perl T.M., Russell P.K., Tonat K., for the working group on civilian biodefense, Anthrax as a biological weapon, 2002: updated recommendations for management. J Am Med Assoc, 2002, 287, 2236-2252. [Google Scholar]
- Laffly E., Danjou L., Condemine F., Vidal D., Drouet E., Lefranc M.P., Bottex C., Thullier P., Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother, 2005, 49, 3414-3420. [Google Scholar]
- Laffly E., Pelat T., Cedrone F., Blesa S., Bedouelle H., Thullier P., Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Bio, 2008, 378, 1094-1103. [CrossRef] [Google Scholar]
- Loving C.L., Kennett M., Lee G.M., Grippe V.K., Merkel T.J., Murine aerosol challenge model of anthrax. Infect Immun, 2007, 75, 2689-2698. [CrossRef] [PubMed] [Google Scholar]
- Mock M., Fouet A., Anthrax., Annu Rev Microbiol, 2001, 55, 647-671. [Google Scholar]
- Mohamed N., Clagett M., Li J., Jones S., Pincus S., D'Alia G., Nardone L., Babin M., Spitalny G., Casey L., A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun, 2005, 73, 795-802. [Google Scholar]
- Pelat T., Hust M., Laffly E., Condemine F., Bottex C., Vidal D., Lefranc M.P., Dubel S., Thullier P., A high affinity, human-like antibody fragment (scFv) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibting PA-LF complex formation. Antimicrob Agents Chemother, 2007, 51, 2758-2764. [Google Scholar]
- Pelat T., Bedouelle H., Rees A.R., Crennell S.J., Lefranc M.P., Thullier P., Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Bio, 2008, 384, 1400-1407. [Google Scholar]
- Peterson J.W., Comer J.E., Baze W.B., Noffsinger D.M., Wenglikowski A., Walberg K.G., Hardcastle J., Pawlik J., Bush K., Taormina J., Moen S., Thomas J., Chatuev B.M., Sower L., Chopra A.K., Stanberry L.R., Sawada R., Scholz W.W., Sircar J., Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun, 2007, 75, 3414-3424. [Google Scholar]
- Peterson J.W., Comer J.E., Noffsinger D.M., Wenglikowski A., Walberg K.G., Chatuev B.M., Chopra A.K., Stanberry L.R., Kang A.S., Scholz W.W., Sircar J., Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun, 2006, 74, 1016-1024. [Google Scholar]
- Sawada-Hirai R., Jiang I., Wang F., Sun S.M., Nedellec R., Ruther P., Alvarez A., Millis D., Morrow P.R., Kang A.S., Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immun Based Ther Vaccines, 2004, 12, 5. [Google Scholar]
- Shen Y., Zhukovskaya N.L., Guo Q., Florian J., Tang W.J., Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J, 2005, 24, 929-941. [CrossRef] [PubMed] [Google Scholar]
- Steiniger S.C., Altobell L.J. 3rd, Zhou B., Janda K.D., Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen. Mol Immun, 2007, 44, 2749-2755. [CrossRef] [Google Scholar]
- Sylvestre P., Fouet A., Mock M., In de Revel T., Gourmelon P., Vidal D., Renaudeau C. (Eds.), Menace terroriste. Nucléaire, radiologique, biologique, chimique. Approche médicale, 2005 John Libbey Eurotext Edition, pp. 175-183. [Google Scholar]
- Tournier J.N., Quesnel-Hellmann A., Mathieu J., Montecucco C., Tang W.J., Mock M., Vidal D.R., Goossens P.L., Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immun, 2005, 174, 4934-4941. [Google Scholar]
- Turnbull P.C.B., In Khoeler T.M. (Ed.), Anthrax history, disease and ecology., Anthrax, 2002 Springer Verlag, Berlin, pp. 1-18. [Google Scholar]
- Vaissaire J., Mock M., Le Doujet C., Lévy M., Le charbon bactéridien. Epidémiologie de la maladie en France. Med Mal infec, 2001, 31, 257-271. [Google Scholar]
- Vitale L., Blanset D., Lowy I., O'Neill T., Goldstein J., Little S.F., Andrews G.P., Dorough G., Taylor R.K., Keler T., Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun, 2006, 74, 5840-5847. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.